Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring
نویسندگان
چکیده
BACKGROUND A definitive diagnosis of multiple sclerosis (MS), as distinct from a clinically isolated syndrome, requires one of two conditions: a second clinical attack or particular magnetic resonance imaging (MRI) findings as defined by the McDonald criteria. MRI is also important after a diagnosis is made as a means of monitoring subclinical disease activity. While a standardized protocol for diagnostic and follow-up MRI has been developed by the Consortium of Multiple Sclerosis Centres, acceptance and implementation in Canada have been suboptimal. METHODS To improve diagnosis, monitoring, and management of a clinically isolated syndrome and MS, a Canadian expert panel created consensus recommendations about the appropriate application of the 2010 McDonald criteria in routine practice, strategies to improve adherence to the standardized Consortium of Multiple Sclerosis Centres MRI protocol, and methods for ensuring effective communication among health care practitioners, in particular referring physicians, neurologists, and radiologists. RESULTS This article presents eight consensus statements developed by the expert panel, along with the rationale underlying the recommendations and commentaries on how to prioritize resource use within the Canadian healthcare system. CONCLUSIONS The expert panel calls on neurologists and radiologists in Canada to incorporate the McDonald criteria, the Consortium of Multiple Sclerosis Centres MRI protocol, and other guidance given in this consensus presentation into their practices. By improving communication and general awareness of best practices for MRI use in MS diagnosis and monitoring, we can improve patient care across Canada by providing timely diagnosis, informed management decisions, and better continuity of care.
منابع مشابه
Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations
BACKGROUND Magnetic resonance imaging (MRI) is increasingly important for the early detection of suboptimal responders to disease-modifying therapy for relapsing-remitting multiple sclerosis. Treatment response criteria are becoming more stringent with the use of composite measures, such as no evidence of disease activity (NEDA), which combines clinical and radiological measures, and NEDA-4, wh...
متن کاملUse of Natalizumab in Patients with Multiple Sclerosis: 2015 Update.
Natalizumab is a monoclonal antibody indicated in Canada as monotherapy for the treatment of multiple sclerosis (MS) patients with relapsing-remitting disease. Although natalizumab has been available in Canada since 2006, there remain elements of uncertainty among community and academic neurologists on how best to use this drug in clinical practice. The following recommendations relating to the...
متن کاملRecommendations for the use of ultrasound and magnetic resonance in patients with rheumatoid arthritis.
OBJECTIVE To develop evidence-based recommendations on the use of ultrasound (US) and magnetic resonance imaging (MRI) in patients with rheumatoid arthritis (RA). METHODS Recommendations were generated following a nominal group technique. A panel of experts, consisting of 15 rheumatologists and 3 radiologists, was established in the first panel meeting to define the scope and purpose of the c...
متن کاملGuidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
Multiple sclerosis (MS) is associated with inflammatory lesions in the brain and spinal cord. The detection of such inflammatory lesions using magnetic resonance imaging (MRI) is important in the consideration of the diagnosis and differential diagnoses of MS, as well as in the monitoring of disease activity and predicting treatment efficacy. Although there is strong evidence supporting the use...
متن کاملUse of natalizumab in multiple sclerosis patients.
Natalizumab is a monoclonal antibody indicated in Canada as monotherapy for the treatment of multiple sclerosis (MS) patients with relapsing-remitting disease. The phase III clinical trial of natalizumab monotherapy demonstrated substantial improvements in clinical and magnetic resonance imaging (MRI) parameters in patients with relapsing-remitting MS, with statistically significant reductions ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 42 شماره
صفحات -
تاریخ انتشار 2015